Long-Lasting Effects of Methocinnamox on Opioid Self-Administration in Rhesus Monkeys.

Analgesics, Opioid / administration & dosage Animals Cinnamates / pharmacology Drug-Seeking Behavior / drug effects Female Macaca mulatta Male Morphine Derivatives / pharmacology Naltrexone / pharmacology Narcotic Antagonists / pharmacology Receptors, Opioid, mu / antagonists & inhibitors Self Administration Time Factors

Journal

The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362

Informations de publication

Date de publication:
01 2019
Historique:
received: 26 07 2018
accepted: 05 11 2018
pubmed: 8 11 2018
medline: 2 11 2019
entrez: 8 11 2018
Statut: ppublish

Résumé

Opioid abuse remains a serious public health challenge, despite the availability of medications that are effective in some patients (naltrexone, buprenorphine, and methadone). This study explored the potential of a pseudoirreversible mu-opioid receptor antagonist [methocinnamox (MCAM)] as a treatment for opioid abuse by examining its capacity to attenuate the reinforcing effects of mu-opioid receptor agonists in rhesus monkeys. In one experiment, monkeys responded for heroin (

Identifiants

DOI: 10.1124/jpet.118.252353 PMID: 30401680
pubmed: 30401680
pii: jpet.118.252353
doi: 10.1124/jpet.118.252353
doi:

Substances chimiques

Analgesics, Opioid 0
Cinnamates 0
Morphine Derivatives 0
Narcotic Antagonists 0
Receptors, Opioid, mu 0
methocinnamox 0
Naltrexone 5S6W795CQM

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

88-99

Subventions

Organisme : NIDA NIH HHS
ID : P01 DA000254
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA005018
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA007315
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA048417
Pays : United States

Informations de copyright

Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Auteurs

David R Maguire (DR)

Department of Pharmacology (D.R.M., L.R.G., J.H.W., C.P.F.), Department of Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (D.R.M., L.R.G., J.H.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (S.M.H., A.D.).

Lisa R Gerak (LR)

Department of Pharmacology (D.R.M., L.R.G., J.H.W., C.P.F.), Department of Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (D.R.M., L.R.G., J.H.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (S.M.H., A.D.).

James H Woods (JH)

Department of Pharmacology (D.R.M., L.R.G., J.H.W., C.P.F.), Department of Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (D.R.M., L.R.G., J.H.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (S.M.H., A.D.).

Stephen M Husbands (SM)

Department of Pharmacology (D.R.M., L.R.G., J.H.W., C.P.F.), Department of Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (D.R.M., L.R.G., J.H.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (S.M.H., A.D.).

Alex Disney (A)

Department of Pharmacology (D.R.M., L.R.G., J.H.W., C.P.F.), Department of Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (D.R.M., L.R.G., J.H.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (S.M.H., A.D.).

Charles P France (CP)

Department of Pharmacology (D.R.M., L.R.G., J.H.W., C.P.F.), Department of Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (D.R.M., L.R.G., J.H.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (S.M.H., A.D.) france@uthscsa.edu.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Dépresseurs du système nerveux central › Stupéfiants › Analgésiques morphiniques › Long-Lasting Effects of Methocinnamox on...
questionsmedicales.fr › Eucaryotes › Animaux › Long-Lasting Effects of Methocinnamox on...
questionsmedicales.fr › Composés chimiques organiques › Acides carboxyliques › Acides carbocycliques › Cinnamates › Long-Lasting Effects of Methocinnamox on...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Comportement › Comportement de recherche de substances › Long-Lasting Effects of Methocinnamox on...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Cercopithecidae › Cercopithecinae › Macaca › Macaca mulatta › Long-Lasting Effects of Methocinnamox on...
questionsmedicales.fr › Composés polycycliques › Hydrocarbures aromatiques polycycliques › Phénanthrènes › Morphinanes › Dérivés de la morphine › Long-Lasting Effects of Methocinnamox on...
questionsmedicales.fr › Composés polycycliques › Hydrocarbures aromatiques polycycliques › Phénanthrènes › Morphinanes › Naloxone › Naltrexone › Long-Lasting Effects of Methocinnamox on...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Antagonistes narcotiques › Long-Lasting Effects of Methocinnamox on...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur aux neuropeptides › Récepteurs aux opioïdes › Récepteur mu › Long-Lasting Effects of Methocinnamox on...
questionsmedicales.fr › Thérapeutique › Autoadministration › Long-Lasting Effects of Methocinnamox on...
questionsmedicales.fr › Phénomènes physiques › Temps › Facteurs temps › Long-Lasting Effects of Methocinnamox on...